Stock Events

Stock Events

Relmada Therapeutics 

$6.37
33
-$0.01-0.16% Monday 03:11

Statistics

Day High
6.37
Day Low
6.31
52W High
-
52W Low
-
Volume
258
Avg. Volume
-
Mkt Cap
211.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.42
-0.33
-0.24
-0.15
Expected EPS
-0.20034
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-159.96MNet Income

Analyst Ratings

$12.40Average Price Target
The highest estimate is 19.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RLMD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes develops treatments for major depressive disorder and other central nervous system disorders, overlapping with Relmada's focus.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the mental health space.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a strong portfolio in psychiatric and neurological conditions, directly competing with Relmada's offerings.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of products for neurological and psychiatric conditions, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a focus on CNS and pain, areas that Relmada is also targeting.
Novartis
NVS
Mkt Cap237.61B
Novartis offers medications for a wide range of neurological conditions, competing in the same market as Relmada.
Merck
MRK
Mkt Cap214.76B
Merck & Co. has initiatives in brain health, including treatments for conditions that Relmada targets.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a growing portfolio in neuroscience, including treatments for psychiatric disorders.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a diverse neuroscience portfolio, making it a competitor in the mental health treatment market.

About

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Show more...
CEO
ISIN
US75955J4022

Listings

XNAS
US
RLMD
F
DE
4E2.F
BOATS
BOATS
RLMD.BOATS

0 Comments

Share your thoughts

FAQ

What is Relmada Therapeutics stock price today?▼
The current price of RLMD.BOATS is $6.37 USD — it has decreased by -0.16% in the past 24 hours. Watch Relmada Therapeutics stock price performance more closely on the chart.
What is Relmada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Relmada Therapeutics stocks are traded under the ticker RLMD.BOATS.
What is Relmada Therapeutics market cap?▼
Today Relmada Therapeutics has the market capitalization of 211.43M
When is the next Relmada Therapeutics earnings date?▼
Relmada Therapeutics is going to release the next earnings report on May 13, 2026.
What were Relmada Therapeutics earnings last quarter?▼
RLMD.BOATS earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.15 USD resulting in a -81.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Relmada Therapeutics revenue for the last year?▼
Relmada Therapeutics revenue for the last year amounts to 0 USD.
What is Relmada Therapeutics net income for the last year?▼
RLMD.BOATS net income for the last year is -159.96M USD.
When did Relmada Therapeutics complete a stock split?▼
Relmada Therapeutics has not had any recent stock splits.